Valuation: CSL Limited

Market Cap 39.52B 34.63B 32.15B 29.54B 55.66B 3,814B 56.48B 383B 150B 1,866B 148B 145B 6,446B P/E 2026 *
-44.3x
P/E 2027 * 27.4x
Enterprise Value 48.41B 42.42B 39.38B 36.19B 68.19B 4,672B 69.19B 469B 184B 2,286B 182B 178B 7,897B EV / Sales 2026 *
3.15x
EV / Sales 2027 * 3.06x
Free-Float
99.3%
Yield 2026 *
3.45%
Yield 2027 * 3.55%
1 day-1.86%
1 week-5.08%
Current month+0.88%
1 month+3.31%
3 months-10.27%
6 months-35.56%
Current year-32.96%
1 week 115.69
Extreme 115.69
124.83
1 month 112.4
Extreme 112.4
126.98
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
275.79
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap.
6/1/26 Buy

Director

1,036 0.0002%
5/26/26 Buy

Chief Executive Officer

1,100 0.0002%
5/26/26 Buy

Chief Executive Officer

1,100 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-1.86%-5.08%-56.40%-56.53% 39.52B
-3.56%-2.00%+16.09%-11.36% 66.25B
-0.78%+1.56%+35.73%+196.49% 52.86B
-1.65%+37.20%+37.20%+37.20% 43.01B
-2.67%+0.25%+54.67%-28.55% 29.19B
-2.67%-14.95%+77.42%-54.07% 23.04B
-1.36%+0.61%+68.06%+80.50% 23.13B
-1.14%-3.13%+3.69%+174.85% 20.48B
-1.27%+1.58%+71.18%+122.26% 16.6B
+0.25%0.00%+80.60%+142.19% 16.2B
Average -1.66%-1.86%+38.82%+60.30% 33.03B
Weighted average by Cap. -1.91%-1.46%+29.80%+50.55%

Financials

2026 *2027 *
Net sales 15.39B 13.48B 12.52B 11.5B 21.68B 1,485B 22B 149B 58.37B 727B 57.77B 56.53B 2,510B 15.61B 13.67B 12.69B 11.66B 21.98B 1,506B 22.3B 151B 59.19B 737B 58.58B 57.32B 2,545B
Net income -972M -851M -790M -726M -1.37B -93.75B -1.39B -9.41B -3.68B -45.87B -3.65B -3.57B -158B 1.19B 1.04B 969M 890M 1.68B 115B 1.7B 11.54B 4.52B 56.23B 4.47B 4.37B 194B
Net Debt 8.89B 7.79B 7.23B 6.65B 12.53B 858B 12.71B 86.18B 33.73B 420B 33.39B 32.67B 1,451B 8.16B 7.15B 6.64B 6.1B 11.49B 788B 11.66B 79.08B 30.95B 385B 30.64B 29.98B 1,331B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
26-07-23 A$115.75 -1.86% 1,250,961
26-07-22 A$117.94 -2.83% 1,089,586
26-07-21 A$121.38 -1.00% 892,794
26-07-20 A$122.61 -0.58% 672,117
26-07-17 A$123.32 +1.12% 1,621,401
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
82.52USD
Average target price
96.91USD
Spread / Average Target
+17.44%

Quarterly revenue - Rate of surprise